TrialCancer medicine2021

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.

Judith Passildas-Jahanmohan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.